EUVIMEDEUVIMED entdecken
Crossref

Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools

Steven Weisman

Federal Practitioner · 03.11.2026 · 43 (Suppl 5)

DOI: 10.12788/fp.0778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Federal Practitioner, online erschienen am 03.11.2026. Verfasst von Steven Weisman.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Weisman, S. (2026). Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools. Federal Practitioner, 43(Suppl 5). https://doi.org/10.12788/fp.0778

Vancouver

Weisman S. Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools. Federal Practitioner. 2026;43(Suppl 5). doi:10.12788/fp.0778

BibTeX
@article{Weisman2026,
  author = {Weisman, Steven},
  title = {Revisiting the Low-Dose Aspirin Benefit-Risk Discussion in the Context of New Risk Assessment Tools},
  journal = {Federal Practitioner},
  year = {2026},
  volume = {43},
  number = {Suppl 5},
  doi = {10.12788/fp.0778}
}
Kostenlos starten →